Patents by Inventor Mireille Gillings

Mireille Gillings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SULCARDINE ADMINISTRATION FOR TREATMENT OF ACUTE ATRIAL FIBRILLATION 94919.0739.717301US
    Publication number: 20240058304
    Abstract: Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.
    Type: Application
    Filed: October 11, 2023
    Publication date: February 22, 2024
    Inventors: Gary ELLIOTT, Mireille GILLINGS, Robert GOODENOW, Jay MASON, Waldemar RADZISZEWSKI, Suzanne ROMANO
  • COMBINATION THERAPIES OF WDR-5 INHIBITORS AND PD-1 INHIBITORS
    Publication number: 20240041865
    Abstract: Provided herein are combinations that include a WDR5 inhibitor and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. Provided herein also include pharmaceutical compositions for cancer treatment, including a WDR5 inhibitor and a PD-1 inhibitor. The combinations recited herein are also useful for regulating the response of immune cells in a cancer microenvironment.
    Type: Application
    Filed: July 12, 2023
    Publication date: February 8, 2024
    Inventors: Farbod SHOJAEI, Jill M. RICONO, Mireille GILLINGS, Fairooz KABBINAVAR
  • Sulcardine administration for treatment of acute atrial fibrillation
    Patent number: 11813245
    Abstract: Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: November 14, 2023
    Assignee: HUYABIO International, LLC
    Inventors: Gary Elliott, Mireille Gillings, Robert Goodenow, Jay Mason, Waldemar Radziszewski, Suzanne Romano
  • MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR COMPOUNDS AND USES THEREOF
    Publication number: 20230293539
    Abstract: Described herein are phenyl triazole and aniline compounds that are MLL1-WDR5 protein-protein interaction inhibitors. Also disclosed herein are pharmaceutical compositions and methods of use for the phenyl triazole and the aniline compounds.
    Type: Application
    Filed: March 10, 2023
    Publication date: September 21, 2023
    Inventors: Farbod SHOJAEI, Che FANG, J. Edward SEMPLE, Mireille GILLINGS
  • PHENYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR
    Publication number: 20230286925
    Abstract: Described herein are a phenyl triazole MLL1-WDR5 protein-protein interaction inhibitors, pharmaceutical compositions and methods of use.
    Type: Application
    Filed: March 10, 2023
    Publication date: September 14, 2023
    Inventors: Qidong YOU, Xiaoke GUO, Farbod SHOJAEI, Xin CHEN, J. Edward SEMPLE, Zhengyu JIANG, Xiaoli XU, Mireille GILLINGS
  • HALOALKYLPYRIDYL TRIAZOLE MLL1-WDR5 PROTEIN-PROTEIN INTERACTION INHIBITOR
    Publication number: 20230286948
    Abstract: Described herein are a haloalkylpyridyl triazole MLL1-WDR5 protein-protein interaction inhibitors, pharmaceutical compositions and methods of use.
    Type: Application
    Filed: March 10, 2023
    Publication date: September 14, 2023
    Inventors: Farbod SHOJAEI, J. Edward SEMPLE, Mireille GILLINGS
  • COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS
    Publication number: 20230151099
    Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.
    Type: Application
    Filed: November 23, 2022
    Publication date: May 18, 2023
    Inventors: Reid P. BISSONNETTE, Alain ROLLAND, Mireille GILLINGS
  • Combination therapies of HDAC inhibitors and PD-L1 inhibitors
    Patent number: 11535670
    Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: December 27, 2022
    Assignee: HUYABIO International, LLC
    Inventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings
  • COMBINATION THERAPIES COMPRISING SHP2 INHIBITORS AND EGFR TYROSINE KINASE INHIBITORS
    Publication number: 20220370456
    Abstract: Provided herein are combinations that include a SHP2 inhibitor and an EGFR TKI and methods of treating cancer.
    Type: Application
    Filed: May 4, 2022
    Publication date: November 24, 2022
    Inventors: Farbod SHOJAEI, Jill M. RICONO, Robert GOODENOW, Mireille GILLINGS
  • COMBINATION THERAPIES COMPRISING SHP2 INHIBITORS AND PD-1 INHIBITORS
    Publication number: 20220370457
    Abstract: Provided herein are combinations that include a SHP2 inhibitor and a PD-1 inhibitor and methods of treating cancer.
    Type: Application
    Filed: May 4, 2022
    Publication date: November 24, 2022
    Inventors: Farbod SHOJAEI, Jill M. RICONO, Robert GOODENOW, Mireille GILLINGS
  • SHP2 INHIBITOR MONOTHERAPY AND USES THEREOF
    Publication number: 20220370458
    Abstract: Provided herein are SHP2 inhibitors for use in the reduction of solid tumors in a method of treating cancer.
    Type: Application
    Filed: May 4, 2022
    Publication date: November 24, 2022
    Inventors: Farbod SHOJAEI, Jill M. RICONO, Robert GOODENOW, Mireille GILLINGS
  • SULCARDINE SALTS
    Publication number: 20220356319
    Abstract: Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.
    Type: Application
    Filed: July 11, 2022
    Publication date: November 10, 2022
    Inventors: Suzanne J. ROMANO, Hayley Ann REECE, Joseph Edward Gordon BENSON, Sarah COLLINS, Gary T. ELLIOTT, Mireille GILLINGS, Robert GOODENOW, Curtis TYREE
  • Sulcardine salts
    Patent number: 11426382
    Abstract: Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: August 30, 2022
    Assignee: HUYABIO International, LLC
    Inventors: Suzanne J. Romano, Hayley Ann Reece, Joseph Edward Gordon Benson, Sarah Collins, Gary T. Elliott, Mireille Gillings, Robert Goodenow, Curtis Tyree
  • METHODS AND COMPOSITIONS FOR GENETIC MODULATION OF TUMOR MICROENVIRONMENTS
    Publication number: 20220110924
    Abstract: Provided herein is a therapy comprising an HDAC inhibitor (HDACi), and/or a PD-L1 and/or a PD-1 inhibitor, and/or a CTLA-4 inhibitor. The combination therapy provided herein can be a kit or the composition or a pharmaceutical composition. Also, provided herein is a method of treating cancer using the combination therapy.
    Type: Application
    Filed: August 24, 2021
    Publication date: April 14, 2022
    Inventors: Reid P. BISSONNETTE, Rosemary M. CESARIO, Robert GOODENOW, Farbod SHOJAEI, Mireille GILLINGS
  • SULCARDINE ADMINISTRATION FOR TREATMENT OF ACUTE ATRIAL FIBRILLATION
    Publication number: 20210386708
    Abstract: Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.
    Type: Application
    Filed: June 11, 2021
    Publication date: December 16, 2021
    Inventors: Gary ELLIOTT, Mireille GILLINGS, Robert GOODENOW, Jay MASON, Waldemar RADZISZEWSKI, Suzanne ROMANO
  • Sulcardine salts
    Patent number: 11020374
    Abstract: Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: June 1, 2021
    Assignee: HUYA Bioscience International, LLC
    Inventors: Suzanne J. Romano, Hayley Ann Reece, Joseph Edward Gordon Benson, Sarah Collins, Gary T. Elliott, Mireille Gillings, Robert Goodenow, Curtis Tyree
  • SULCARDINE SALTS
    Publication number: 20210038568
    Abstract: Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 11, 2021
    Inventors: Suzanne J. ROMANO, Hayley Ann REECE, Joseph Edward Gordon BENSON, Sarah COLLINS, Gary T. ELLIOTT, Mireille GILLINGS, Robert GOODENOW, Curtis TYREE
  • TRIPLET THERAPIES OF HDAC INHIBITORS, PD-L1 AND/OR PD-1 INHIBITORS, AND CTLA-4 INHIBITORS
    Publication number: 20200383961
    Abstract: Provided herein is a combination therapy comprising an HDAC inhibitor (HDACi) a PD-L1 and/or a PD-1 inhibitor, and a CTLA-4 inhibitor. The combination therapy provided herein can be a kit or the composition or a pharmaceutical composition. Also, provided herein is a method of treating cancer using the combination therapy.
    Type: Application
    Filed: June 5, 2020
    Publication date: December 10, 2020
    Inventors: Mireille GILLINGS, Reid BISSONNETTE
  • SULCARDINE SALTS
    Publication number: 20200316024
    Abstract: Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.
    Type: Application
    Filed: January 28, 2020
    Publication date: October 8, 2020
    Inventors: Suzanne J. Romano, Hayley Ann Reece, Joseph Edward Gordon Benson, Sarah Collins, Gary T. Elliott, Mireille Gillings, Robert Goodenow, Curtis Tyree
  • COMBINATION THERAPIES OF HDAC INHIBITORS AND PD-L1 INHIBITORS
    Publication number: 20200181267
    Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.
    Type: Application
    Filed: August 14, 2019
    Publication date: June 11, 2020
    Inventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings